1. Home
  2. SHEN vs ARVN Comparison

SHEN vs ARVN Comparison

Compare SHEN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shenandoah Telecommunications Co

SHEN

Shenandoah Telecommunications Co

SELL

Current Price

$10.06

Market Cap

568.1M

ML Signal

SELL

Logo Arvinas Inc.

ARVN

Arvinas Inc.

SELL

Current Price

$6.49

Market Cap

600.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SHEN
ARVN
Founded
1902
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
568.1M
600.2M
IPO Year
1994
2018

Fundamental Metrics

Financial Performance
Metric
SHEN
ARVN
Price
$10.06
$6.49
Analyst Decision
Buy
Buy
Analyst Count
2
15
Target Price
★ $27.50
$14.00
AVG Volume (30 Days)
561.9K
★ 879.9K
Earning Date
10-28-2026
11-03-2026
Dividend Yield
★ 1.09%
N/A
EPS Growth
N/A
★ 58.84
EPS
N/A
★ 0.88
Revenue
★ $357,854,000.00
$262,600,000.00
Revenue This Year
$4.66
$5.67
Revenue Next Year
$5.27
N/A
P/E Ratio
★ N/A
$7.69
Revenue Growth
★ 9.08
N/A
52 Week Low
$9.13
$6.33
52 Week High
$17.35
$14.20

Technical Indicators

Market Signals
Indicator
SHEN
ARVN
Relative Strength Index (RSI) 44.75 37.66
Support Level $9.29 N/A
Resistance Level $10.48 $7.85
Average True Range (ATR) 0.40 0.46
MACD 0.07 -0.03
Stochastic Oscillator 52.61 10.00

Price Performance

Historical Comparison
SHEN
ARVN

About SHEN Shenandoah Telecommunications Co

Shenandoah Telecommunications Co with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: